[Clinical development of biomarkers for personalized medicine].
Recent progress in a number of molecular profiling technologies and molecular target agents allow the development of personalized medicine. Biomarkers play a critical role in drug discovery, development, and prediction of treatment response and safety. Reliable biomarkers improve disease understanding, and make it possible to tailor medication use in individual patients with the goals of enhancing efficacy and minimizing toxicity. Recently, several important breakthroughs have occurred, such as the identification of a mechanism of resistance to EGFR monoclonal antibodies in colorectal cancer, which may be followed by further predictive tests leading to a reduction of ineffective therapies. This paper focuses on the state of the biomarkers and its clinical applications for personalized medicine.
Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East.
Mayuko
M
Saito
Takayuki
T
Yoshino
D015415:Biomarkers; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D066246:ErbB Receptors; D014453:Glucuronosyltransferase; D006801:Humans; D057285:Precision Medicine; D011379:Prognosis; D011518:Proto-Oncogene Proteins; D019009:Proto-Oncogene Proteins c-kit; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; D018631:ras Proteins; D000099148:UGT1A1 Enzyme
D015415:Biomarkers; D066246:ErbB Receptors; D014453:Glucuronosyltransferase; D011518:Proto-Oncogene Proteins; D019009:Proto-Oncogene Proteins c-kit; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; D018631:ras Proteins; D000099148:UGT1A1 Enzyme; C117307:KRAS protein, human; C512478:EGFR protein, human; C508053:ERBB2 protein, human